Amarin Corp Plcuk AMRN
NASDAQ AMRN
$14.09 +0.03 (+0.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024)

Amarin Corp Plc\Uk (AMRN) posted quarterly Non-Current Deffered Revenue of $2.1 million for Q1 2024, down 83.4% year-over-year from $12.7 million in Q2 2023, and down 15.98% quarter-over-quarter from $2.5 million in Q4 2023.

Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024) Analysis & Trends

Amarin Corp Plc\Uk (AMRN) has reported Non-Current Deffered Revenue for 10 consecutive years, with $2.1 million the latest figure, recorded in Q1 2024.

  • In Q1 2024, Non-Current Deffered Revenue fell 83.4% year-over-year to $2.1 million; the TTM figure through Mar 2024 stood at $2.1 million (down 83.4% YoY), while the FY2023 annual figure was $2.5 million, down 80.92% from the prior year.
  • Non-Current Deffered Revenue declined to $2.1 million in Q1 2024 per AMRN's latest filing, from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $17.5 million in Q1 2020 and bottomed at $2.1 million in Q1 2024.
  • Historically, Non-Current Deffered Revenue has averaged $11.6 million across 5 years, with a median of $13.8 million in 2022.
  • Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue rose 9.75% — and 2024, when it plunged 83.4%.
  • Amarin Corp Plc\Uk's Non-Current Deffered Revenue stood at $15.7 million in 2020, then declined by 10.48% to $14.1 million in 2021, then fell by 6.49% to $13.1 million in 2022, then slumped by 80.92% to $2.5 million in 2023, then fell by 15.98% to $2.1 million in 2024.
  • Business Quant data shows AMRN's Non-Current Deffered Revenue at $2.1 million in Q1 2024, $2.5 million in Q4 2023, and $2.9 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Amarin Corp Plcuk 5.86 Bn 5.54 Bn 14.99 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2024 2.11 Mn
Dec 31, 2023 2.51 Mn
Sep 30, 2023 2.95 Mn
Jun 30, 2023 3.33 Mn
Mar 31, 2023 12.70 Mn
Dec 31, 2022 13.15 Mn
Sep 30, 2022 13.50 Mn
Jun 30, 2022 13.81 Mn
Mar 31, 2022 14.14 Mn
Dec 31, 2021 14.06 Mn
Sep 30, 2021 14.49 Mn
Jun 30, 2021 14.83 Mn
Mar 31, 2021 15.20 Mn
Dec 31, 2020 15.71 Mn
Sep 30, 2020 13.20 Mn
Jun 30, 2020 14.51 Mn
Mar 31, 2020 17.52 Mn
Dec 31, 2019 18.50 Mn
Sep 30, 2019 17.62 Mn
Jun 30, 2019 17.78 Mn